Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compos...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SMID PIETER KOEHLER KONRAD F MLINARIC MICHAEL WEGENER ELMAR NUNEZ GARCIA SARA LANGE JOSEPHUS H. M |
| description | This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US8575148B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US8575148B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US8575148B23</originalsourceid><addsrcrecordid>eNrjZHAILsgsyldIrEotSMxL1c2vSKzKz8lMyczLz0stVkgsVvAuM9QzVijIL0ksLs4szVVIzkjMy0vNUUjKyU_OTi0q5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8aHBFqbmpoYmFk5GxkQoAQBsizET</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers</title><source>esp@cenet</source><creator>SMID PIETER ; KOEHLER KONRAD F ; MLINARIC MICHAEL ; WEGENER ELMAR ; NUNEZ GARCIA SARA ; LANGE JOSEPHUS H. M</creator><creatorcontrib>SMID PIETER ; KOEHLER KONRAD F ; MLINARIC MICHAEL ; WEGENER ELMAR ; NUNEZ GARCIA SARA ; LANGE JOSEPHUS H. M</creatorcontrib><description>This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131105&DB=EPODOC&CC=US&NR=8575148B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131105&DB=EPODOC&CC=US&NR=8575148B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SMID PIETER</creatorcontrib><creatorcontrib>KOEHLER KONRAD F</creatorcontrib><creatorcontrib>MLINARIC MICHAEL</creatorcontrib><creatorcontrib>WEGENER ELMAR</creatorcontrib><creatorcontrib>NUNEZ GARCIA SARA</creatorcontrib><creatorcontrib>LANGE JOSEPHUS H. M</creatorcontrib><title>Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers</title><description>This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAILsgsyldIrEotSMxL1c2vSKzKz8lMyczLz0stVkgsVvAuM9QzVijIL0ksLs4szVVIzkjMy0vNUUjKyU_OTi0q5mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8aHBFqbmpoYmFk5GxkQoAQBsizET</recordid><startdate>20131105</startdate><enddate>20131105</enddate><creator>SMID PIETER</creator><creator>KOEHLER KONRAD F</creator><creator>MLINARIC MICHAEL</creator><creator>WEGENER ELMAR</creator><creator>NUNEZ GARCIA SARA</creator><creator>LANGE JOSEPHUS H. M</creator><scope>EVB</scope></search><sort><creationdate>20131105</creationdate><title>Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers</title><author>SMID PIETER ; KOEHLER KONRAD F ; MLINARIC MICHAEL ; WEGENER ELMAR ; NUNEZ GARCIA SARA ; LANGE JOSEPHUS H. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US8575148B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2013</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SMID PIETER</creatorcontrib><creatorcontrib>KOEHLER KONRAD F</creatorcontrib><creatorcontrib>MLINARIC MICHAEL</creatorcontrib><creatorcontrib>WEGENER ELMAR</creatorcontrib><creatorcontrib>NUNEZ GARCIA SARA</creatorcontrib><creatorcontrib>LANGE JOSEPHUS H. M</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SMID PIETER</au><au>KOEHLER KONRAD F</au><au>MLINARIC MICHAEL</au><au>WEGENER ELMAR</au><au>NUNEZ GARCIA SARA</au><au>LANGE JOSEPHUS H. M</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers</title><date>2013-11-05</date><risdate>2013</risdate><abstract>This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R1, R2, (R3)n, and (R4)m have the meanings given in the specification.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US8575148B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T13%3A02%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SMID%20PIETER&rft.date=2013-11-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS8575148B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |